Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community
|
|
- Allen Webb
- 6 years ago
- Views:
Transcription
1 E088 Essential Shared Care Agreement (South Staffordshire): Aciclovir Administration in the Community Patient s name: DOB NHS Number Patient s address: Consultant Note: Shared care agreement sets out a statement of Specialist Unit /CCN responsibilities. The agreement ensures that CCN s have sufficient information to enable them to take responsibility for administration of medication to children in the Community who may otherwise be in hospital or under the care of an acute trust. ESCA should be available whenever higher than minimal level of risk is involved (agreed by the Trust s Medicines Optimisation Committee) All reasonable requests will be considered however any CCN who does not wish to undertake the clinical and legal responsibility for administering tobramycin is not obliged to do so. Acceptance of the Shared Care Guidelines should be endorsed by the medicines management team of the CCG/ Acute Trust concerned. The information contained in this guideline is issued on the understanding that it is the best available from the resources at our disposal at the time of issue. For further information please refer to the relevant Summary of Product Characteristics ( and NICE guidance or contact your local Specialist or Drug Information Centre. Produced: March 2018 Review date: March 2021 Replaces: - one copy to CCN team - one copy to the patient - one copy to specialist unit Page 1 of 5
2 SHARED CARE GUIDELINES FOR Aciclovir Administration in Children Referral criteria When initiation is by an acute Trust, the patient will receive supplies of Aciclovir medication on a hospital or community prescription form. The prescription chart shall remain with the patient. A faxed copy of the prescription will need to be sent to the CCN before the medication is due to be given so that it can be checked. The patient will have an individual prescription programme defined for them and the CCN will receive a copy of this. A named key worker will have been identified on the CCN team to coordinate the medication plan. Specialist service s responsibilities Establish a diagnosis. Assess the patients suitability for home care, determine a clinical management plan and obtain consent from parents / carers for home care after identifying any risk.. Prescribe patient medication dose and length of treatment. Hold medication protocol/guidelines which can be available to CCN team to include clear information in respect of monitoring requirements. Discuss the benefits and side effects of treatment with the patient. Ensure that the CCN team have agreed to administer the medication as prescribed; appropriate clinical guidelines and protocols should be provided by the prescribing specialist service. Inform GP that child will be receiving Teicoplanin at home. The patient will receive supplies of medication, diluents and disposable supplies (syringes, needles etc) from the hospital for the prescribed course of treatment. Prescription will include; Patient details;age; DOB; Weight; allergies; Dose; infusion rate; diluent ;treatment end date Prescribing clinician needs to clarify specific monitoring requirements, and identify responsible lead clinician (see Below) Alert CCN if monitoring requirements change Have a mechanism in place to receive rapid referral of a patient from the CCN in the event of concerns in patient s clinical condition, and to provide all other review and monitoring (other than that specifically clarified and agreed above). Report adverse events to the MHRA Page 2 of 5
3 Side effects CCN need to be aware of : Dosage in children: Neonates and infants up to 3 months of age: The dosage of Aciclovir 25 mg/ml Concentrate for Solution for Infusion in neonates and infants up to 3 months of age is calculated on the basis of bodyweight. The recommended regimen of Aciclovir 25mg/ml Concentrate for Solution for Infusion for known or suspected neonatal herpes infections is 20 mg/kg bodyweight every 8 hours for 21 days for disseminated and CNS disease, or for 14 days for disease limited to the skin and mucous membranes. Children aged between 3 months and 12 years: The dose of Aciclovir 25 mg/ml Concentrate for Solution for Infusion for children aged between 3 months and 12 years is calculated on the basis of body surface area. Children with Herpes simplex (except herpes encephalitis) or Varicella zoster infections (with normal immune response) should be given Aciclovir 25 mg/ml Concentrate for Solution for Infusion in doses of 250 mg/m 2 of body surface area every 8 hours if renal function is not impaired. In immunocompromised children with Varicella zoster infections or children with herpes encephalitis, Aciclovir 25 mg/ml Concentrate for Solution for Infusion should be given in doses of 500 mg per square metre body surface area every 8 hours if renal function is not impaired. Infants and children with impaired renal function: Infants and children with impaired renal function require an appropriately modified dose, according to the degree of impairment (see Dosage in renal impairment). Dosage in renal impairment: Caution is advised when administering Aciclovir 25 mg/ml Concentrate for Solution for Infusion to patients with impaired renal function since the drug is excreted through the kidneys. Adequate hydration should be maintained. Dosage adjustment for patients with renal impairment is based on creatinine clearance, in units of ml/min for adults and adolescents and in units of ml/min/1.73m2 for infants and children less than 13 years of age. The following adjustments in dosage are suggested: Dosage adjustments in adults and adolescents: Creatinine clearance Dosage 25 to 50 ml/min The dose recommended above (5 or 10 mg/kg bodyweight) should be given every 12 hours. 10 to 25 ml/min The dose recommended above (5 or 10 mg/kg bodyweight) should be given every 24 hours. 0 (anuric) to 10 ml/min In patients receiving continuous ambulatory peritoneal dialysis (CAPD) the dose recommended above (5 or 10 mg/kg bodyweight) should be halved and administered every 24 hours. In patients receiving haemodialysis the dose recommended above (5 or 10 mg/kg bodyweight) should be halved and administered every 24 hours and after dialysis. Page 3 of 5
4 Dosage adjustment in infants and children less than 13 years of age : Creatinine clearance Dosage 25 to 50 ml/min/1.73 m 2 The dose recommended above (250 or 500 mg/m 2 body surface area or 20 mg/kg body weight) should be given every 12 hours. 10 to 25 ml/min/1.73 m 2 The dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be given every 24 hours. 0 (anuric) to 10 ml/min/1.73 m 2 In patients receiving continuous ambulatory peritoneal dialysis (CAPD) the dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be halved and administered every 24 hours. In patients receiving haemodialysis the dose recommended above (250 or 500 mg/m2 body surface area or 20 mg/kg body weight) should be halved and administered every 24 hours and after dialysis. Method of administration The required dose of Aciclovir 25 mg/ml Concentrate for Solution for Infusion should be administered by slow intravenous infusion over a one-hour period and adequate hydration should be established. Aciclovir 25 mg/ml Concentrate for Solution for Infusion may be administered by a controlledrate infusion pump. CCN responsibilities If the CCN declines shared care he/she will notify the consultant without undue delay. When shared care is agreed: Monitor the patient s overall health and well-being. Date / time therapeutic levels to be checked recorded clearly in patient records. Care of IV access site. Report to and seek advice from the specialist on any aspect of patient care that is of concern and may affect treatment. Specific triggers for referral back are: Drug level results fall outside of therapeutic level. CAUTION: NOTE DOSE VARIATION IF RENAL IMPAIRMENT IS PRESENT Refer patient to the specialist if his or her condition deteriorates. Stop treatment on the advice of the specialist or immediately if an urgent need to stop treatment arises. Adverse drug reaction/interaction monitoring Report adverse events to the specialist and serious adverse events to the MHRA. Inform specialist of all relevant medical information regarding the patient. Supporting information on this medicine is available at the team base Page 4 of 5
5 MUST be completed by prescriber MONITORING REQUIRED DATE REQUIRED Therapeutic levels FBC LFT U&E OTHER (specify) Y BLOOD TESTS DATES MUST BE SPECIFIED ON PRESCRIPTION Prescriber Signature: Prescriber Name: Date: Expiry Date of Agreement: Contact Details for Community Childrens Nurses: Contact Name Available Community Childrens 9am-9pm Nurse Stafford everyday Fax Community Childrens Nurse Burton 9am-5pm everyday Ext 2303 / 2305 Fax Page 5 of 5
Essential Shared Care Agreement: Lithium
Ref No. E042 Essential Shared Care Agreement: Lithium Please complete the following details: Patient s name, address, date of birth Treatment (indication, dose regimen, brand name) Monitoring (proposed
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only)
E099 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride (South Staffordshire Only) NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and
More informationE096. Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability
E096 Essential Shared Care Agreement: Melatonin (Circadin ) in Children, adolescents and adults only with Learning Disability Please complete the following details: Patient s name, address, date of birth,
More informationEssential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin)
Ref No: E056 Essential Shared Care Agreement: Melatonin (Circadin, Bio-Melatonin) Please complete the following details: Patient s name, address, date of birth, and either complete when the consultant
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine
Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationDatix Ref:
Title Document Details Shared Care Agreement: Antipsychotics (Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine) Trust Ref No 2081-38933 Local Ref (optional) Main points the document
More informationpatient group direction
ACICLOVIR v01 1/8 ACICLOVIR PGD Details Version 1.0 Legal category Staff grades Approved by POM Paramedic (Non-ECP) Nurse (Non-ECP) Emergency Care Practitioner (Paramedic) Emergency Care Practitioner (Nurse)
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER. Erpizon Lyophilisate for solution for infusion 250 mg/vial Aciclovir
PACKAGE LEAFLET: INFORMATION FOR THE USER Erpizon Lyophilisate for solution for infusion 250 mg/vial Aciclovir 1. DESCRIPTION OF THE MEDICINAL PRODUCT 1.1 Name: ERPIZON 250 mg/vial 1.2 Qualitative composition:
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationWestern Locality Shared care Information ~ Penicillamine, Rheumatology April 2013
Western Locality Shared care Information ~ Penicillamine, Rheumatology April 2013 Penicillamine Treatment of: Rheumatoid arthritis Specialist: Please complete the Shared Care letter sending a request to
More informationESCA: Cinacalcet (Mimpara )
ESCA: Cinacalcet (Mimpara ) Effective Shared Care Agreement for the Treatment of Primary hyperparathyroidism when parathyroidectomy is contraindicated or not clinically appropriate. Specialist details
More informationEssential Shared Care Agreement Naltrexone
In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy
More informationShared Care Agreement for Donepezil
ESCA: for the treatment of Alzheimer s disease SECONDARY CARE SECTION TO BE COMPLETED BY INITIATING DOCTOR Patient s Name: Date of Birth: NHS Number: ESCA Date: One copy of information leaflet given to
More informationShared Care Guideline for Olanzapine (Zyprexa )
Shared Care Guideline for Olanzapine (Zyprexa ) Development Process This guidance has been produced by Sarah Hudson Lead Pharmacist SWYPFT following an AMBER classification status of Olanzapine by the
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More informationNORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE
NORTH AND EAST DEVON HEALTHCARE COMMUNITY SHARED CARE PRESCRIBING GUIDELINE http://www.devonpct.nhs.uk/treatments/ne_devon_shared_care_guidelines.aspx#a Azathioprine Treatment of rheumatological conditions
More informationSULFASALAZINE (Adults)
Shared Care Guideline DRUG: Introduction: SULFASALAZINE (Adults) Indication: Disease modifying drug for rheumatoid arthritis, psoriatic arthritis, undifferentiated arthritis, spondyloarthropathies, Crohn
More informationGuidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting
ANTICOAGULANT SERVICE Guidelines for slow loading of patients on warfarin for Atrial Fibrillation (AF) in the non acute setting Introduction Fast loading of warfarin carries a risk of over anticoagulation
More informationName of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008
Name of Shared Care Agreement: AZATHIOPRINE/6-MERCAPTOPURINE: Oral immunomodulating drugs for inflammatory bowel disease. Reference number: 01/2008 Shared care agreement has been developed appropriately
More informationAzathioprine and Mercaptopurine
This guideline is currently under review. In the interim, the guideline remains valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they have agreed
More informationACIVIR I.V. Injection (Aciclovir)
Published on: 22 Sep 2014 ACIVIR I.V. Injection (Aciclovir) Composition ACIVIR I.V. Each ml contains: Aciclovir BP... 25 mg Water for Injection IP...q.s. Dosage Form Injection for I.V. use Pharmacology
More informationDenosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures
APper apc15-0avgfh7 Shared Care Guideline Denosumab for the treatment of osteoporosis in postmenopausal women at increased risk of fractures For the latest information on interactions and adverse effects,
More informationSHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE LEFLUNOMIDE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationAzathioprine Shared Care Guideline for GPs
Indication: Azathioprine Shared Care Guideline for GPs Active rheumatoid arthritis and other types of inflammatory arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, vasculitis
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More information. AREAS OF RESPONSIBILITY FOR SHARED CARE
SHARED CARE GUIDELINE FOR RILUZOLE IN THE MANAGEMENT OF MOTOR NEURONE DISEASE (MND) SPECIFICALLY AMYOTROPHIC LATERAL SCLEROSIS (ALS) INDICATION This shared care guideline has been prepared to support the
More informationNEW ZEALAND DATA SHEET
1 ACICLOVIR CLARIS (25mg/mL, solution for infusion) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active ingredient Aciclovir (as the sodium salt). For the full list of excipients see section 6.1. 3 PHARMACEUTICAL
More informationMethylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1
More informationMETHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To
More informationFull title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control
Full title of guideline Author: Contact Name and Job Title Division and specialty Scope Explicit definition of patient group to which it applies (e.g. inclusion and exclusion criteria, diagnosis) Changes
More informationSHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS
SHARED CARE PRESCRIBING GUIDELINE AZATHIOPRINE IN ADULT PATIENTS WITH RHEUMATOID ARTHRITIS DOCUMENT DETAILS Document type Shared Care Prescribing Guideline Document name Shared Care Prescribing Guideline:
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex CCG SHARED
More informationViral Infections. 1. Prophylaxis management of patient exposed to Chickenpox:
This document covers: 1. Chickenpox post exposure prophylaxis 2. Chickenpox treatment in immunosuppressed/on treatment patients 3. Management of immunosuppressed exposed to Measles All children with suspected
More informationPaliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016)
Paliperidone Palmitate 3-monthly Long-Acting Injection (Trevicta ) Guidelines for Prescribing and Administration (Version 1 October 2016) 1. Key Points 1.1 Paliperidone palmitate 3-monthly long-acting
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationSERVICE SPECIFICATION 6 Conservative Management & End of Life Care
SERVICE SPECIFICATION 6 Conservative Management & End of Life Care Table of Contents Page 1 Key Messages 2 2 Introduction & Background 2 3 Relevant Guidelines & Standards 2 4 Scope of Service 3 5 Interdependencies
More informationStRs and CT doctors in haematology. September Folinic acid dose modified.
High dose Methotrexate and folinic acid rescue Full Title of Guideline: Author (include email and role): Division & Speciality: Clinical Guideline Review Date September 2018 GUIDELINE FOR THE USE OF HIGH
More informationAREAS OF RESPONSIBILITY FOR THE SHARING OF CARE
Effective Shared Care Agreement (ESCA) Midodrine ESCA: For the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment
More informationTrust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults
A clinical guideline recommended for use: In: By: For: Division responsible for document: Key words: Names of document authors: Job titles of document authors: Name of document author s Line Manager: Job
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD
Ref No: E050 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, or Amisulpride for Behavioural indications in DNLD Please complete the following details: Patient s name,
More informationAdult Neurodevelopmental Services. ADHD Shared Protocol
Adult Neurodevelopmental Services ADHD Shared Protocol Issue 1: April 2016 1 2 Adult Neurodevelopmental Service Shared Care Protocol for Adult Attention Deficit Hyperactivity Disorder (ADHD) 1. BACKGROUND
More informationNorth Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance)
North Derbyshire OPAT (Outpatient Parenteral Antimicrobial Therapy) Pathway for Primary Care (Step-Up Pathway/Admission Avoidance) Introduction OPAT services provide intravenous (IV) antibiotics to patients
More informationAntimicrobial Management of Febrile Neutropenic Sepsis
Antimicrobial Management of Febrile Neutropenic Sepsis Written by: Dr J Joseph, Consultant Haematologist Dr K Gajee, Consultant Microbiologist Amended by: Larissa Claybourn, Antimicrobial Pharmacist Date:
More informationPatient Group Direction for GLUCAGON (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history 31/07/17 V02
More informationBNSSG Shared Care Guidance Please complete all sections
NHS Bristol CCG NHS North Somerset CCG NHS South Gloucestershire CCG North Bristol NHS Trust University Hospitals Bristol NHS Foundation Trust Weston Area Health NHS Trust BNSSG Shared Care Guidance Please
More informationPatient Group Direction for LIDOCAINE INJECTION (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary
More informationThis document expires on Patient Group Direction No. VI 11
Patient Group Direction (PGD) for The Administration of Combined Inactivated Hepatitis A & Hepatitis B Vaccine (Twinrix adult, Twinrix paediatric) to Adults and Children over one year by Registered Nurses
More informationECN Protocol Book. Generic Chemotherapy Protocol Guidelines. ECN_Protocol_Book_generic chemotherapy protocol guidelines guidelines_1
ECN Protocol Book Generic Chemotherapy Protocol Guidelines Name of person presenting document: Reason for document development: Names of development team: Specify groups of staff to whom the document relates:
More information1. QUALITATIVE AND QUANTITATIVE COMPOSITION ZOVIRAX 250 mg: The sodium ion content is approximately 26 mg per vial.
ZOVIRAX IV Aciclovir POWDER FOR I.V. INFUSION 1. QUALITATIVE AND QUANTITATIVE COMPOSITION ZOVIRAX 250 mg: The sodium ion content is approximately 26 mg per vial. 2. PHARMACEUTICAL FORM Freeze dried powder
More informationEffective Shared Care Agreement (ESCA)
Effective Shared Care Agreement (ESCA) Azathioprine (either alone or more usually in combination with corticosteroids and/or other drugs and procedures) ESCA: For the treatment of systemic lupus erythematosus
More informationSHARED CARE PRESCRIBING GUIDELINE
WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex
More informationShared Care Agreement Apomorphine For use in Parkinson s Disease
Shared Care Agreement Apomorphine For use in Parkinson s Disease This shared care agreement outlines suggested ways in which the prescribing responsibilities can be shared between the specialist and GP.
More informationEssential Shared Care Agreement Drugs for Dementia
E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient
More informationINTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS
Title of guideline (must include the word Guideline (not protocol, policy, procedure etc) INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS Author: Contact Name and Job Title
More informationCase scenarios: Patient Group Directions
Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationNHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST
NHS LINCOLNSHIRE in association with UNITED LINCOLNSHIRE HOSPITALS TRUST SHARED CARE GUIDELINE: CINACALCET in the management of secondary hyperparathyroidism in adult patients with end-stage renal disease
More informationPrescribing Framework for Methotrexate for Immunosuppression in ADULTS
Hull & East Riding Prescribing Committee Prescribing Framework for Methotrexate for Immunosuppression in ADULTS Patient s Name:.. NHS Number: Patient s Address:... (Use addressograph sticker) GP s Name:...
More informationSHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN
SHARED CARE GUIDELINE FOR BUCCAL MIDAZOLAM FOR THE TREATMENT OF PROLONGED SEIZURES IN CHILDREN 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the
More information02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical POOLE HOSPITAL NHS FOUNDATION TRUST
Service Specification No. Service Commissioner Leads 02/GMS/0030 ADULT EPILEPSY SERVICE CCP for General Medical and Surgical Provider Lead POOLE HOSPITAL NHS FOUNDATION TRUST Period 1 April 2013 to 31
More informationBortezomib, Thalidomide & Dexamethasone
DRUG ADMINISTRATION SCHEDULE Cumbria, Northumberland, Tyne & Wear Area Team Day Drug Dose Route Diluent Rate 1, 4, 8, & 11 2 Bortezomib 1.3mg/m IV bolus/ SC injection* None Fast bolus: 3 to 5 seconds 1
More informationClinician Responsible for Training and Review: Emergency Department Consultant
Patient Group Direction for the supply and/or administration of Paracetamol Oral Suspension 250mg/5ml (Paracetamol paediatric suspension) to children receiving treatment from NHS Borders services. This
More informationPolicy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical Commissioning Group
BEFORE USING THIS POLICY ALWAYS ENSURE YOU ARE USING THE MOST UP TO DATE VERSION Policy and Procedure for the Development, Approval and Implementation of Patient Group Directions in NHS Haringey Clinical
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give
More informationFrimley Health Area Prescribing Committee
Frimley Health Area Prescribing Committee Frimley Health NHS Foundation Trust North East Hampshire and Farnham CCG East Berkshire CCG Surrey Heath CCG Buckinghamshire CCG SHARED CARE Guideline Amber Traffic
More informationSCHEDULE 2 THE SERVICES
SCHEDULE 2 THE SERVICES A. Service Specifications Mandatory headings 1 4: mandatory but detail for local determination and agreement Optional headings 5-7: optional to use, detail for local determination
More informationMedicines Optimisation Team Standard Operating procedure for Alogliptin Audit:
Medicines Optimisation Team Standard Operating procedure for Alogliptin Audit: To review type 2 diabetic patients prescribed dipedtidylpeptidase-4 (DPP-4) inhibitors (linagliptin (Trajenta, saxagliptin
More informationPrescription only medicines (POMs)
Prescription only medicines (POMs) 2017 Learning objectives Explain the legal framework with which registered health care professionals can administer prescription only medicines Define the role and limitations
More informationClarity around the new editions of the BNF Publications
Clarity around the new editions of the BNF Publications UKMi, the Neonatal and Paediatrics Pharmacy Group (NPPG) and the BNF are aware of a number of discussions and email threads discussing BNF for Children
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More informationWestern Locality Shared care information ~ Azathioprine and Mercaptopurine
The following guidelines are currently under review. In the interim, the guidelines remain valid; if GPs have any specific concerns or questions, they should seek advice from the specialist with whom they
More informationSAMPLE. PGD Reviewed by: Chris Faldon, John Maloney, Tim Patterson, Adrian MacKenzie, Claire Stein
Patient Group Direction for the supply or administration of haemophilus influenzae type B and meningococcal conjugate vaccine to children requiring immunisation as part of the national childhood vaccination
More informationCubicin A Guide to Dosing
Cubicin A Guide to Dosing Cubicin (Daptomycin) powder for solution for injection or infusion Indications (see SmPC) 1 : Cubicin is indicated for the treatment of the following infections (see sections
More informationThis document expires on Patient Group Direction No. VI 7
Patient Group Direction (PGD) for The Administration of Combined low-dose Diphtheria, Tetanus, and Inactivated Polio Vaccine (Revaxis ) to individuals aged over 10 years, by Registered Nurses employed
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationThis document expires on Patient Group Direction Number VI 19
Patient Group Direction (PGD) for The Administration of Pneumococcal Polysaccharide Vaccine (PPV, Pneumovax II ) to adults over 65 years and at risk groups aged 2 years and over, by Registered Nurses employed
More informationChild and Adolescent Mental Health Services (CAMHS)
Child and Adolescent Mental Health Services (CAMHS) Effective shared care agreement (ESCA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with METHYLPHENIDATE This form must be completed
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationTreatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis
Treatment monitoring protocol for Dimethyl fumarate therapy in active Relapsing Remitting Multiple Sclerosis This protocol provides monitoring guidance for adult patients requiring Dimethyl fumarate therapy
More informationGuideline for the Management of Continuous IV Vancomycin Infusion in Neonates on NICU A Clinical Guideline recommended for use
Guideline for the Management of Continuous IV Vancomycin Infusion in A Clinical Guideline recommended for use For Use in: By: For: Division responsible for document: Key words: Name and job title of document
More informationShared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins
Tameside Hospital NHS Foundation Trust and NHS Tameside and Glossop Shared Care Protocol for the Prescription and Supply of Low Molecular Weight Heparins Version 5.2 Version: 5.2 Authorised by: Joint Medicines
More informationfor adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services
The supply of Champix (Varenicline) Tablets 500mcg and 1mg by registered community pharmacists for smoking cessation / management of nicotine withdrawal for adults engaged with the Family Wellbeing Service
More informationPlacename CCG. Policies for the Commissioning of Healthcare
Placename CCG Policies for the Commissioning of Healthcare Policy for the funding of insulin pumps and continuous glucose monitoring devices for patients with diabetes 1 Introduction 1.1 This document
More informationJylamvo 2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals. Information to minimise the risk of medication error
2 mg/ml oral solution (Methotrexate) Guide for Healthcare Professionals Information to minimise the risk of medication error NOTE: Special warnings and precautions for use - This oral solution contains
More informationShared Care Guideline Stepping Hill Hospital and North Derbyshire CCG
Shared Care Guideline Stepping Hill Hospital and North Derbyshire CCG Shared Care Guideline for Sulfasalazine in Rheumatological Conditions in Adults Reference Number Replaces: Issue date: November 2017
More informationDrug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression
SHARED CARE PROTOCOL AND INFORMATION FOR GPS Drug Name: Lithium Clinical Indications: Treatment and prophylaxis of mania; bipolar disorder; augmentation therapy in treatment resistant depression Version:
More informationAnalgesia in patients with impaired renal function Formulary Guidance
Analgesia in patients with impaired renal function Formulary Guidance Approved by Trust D&TC: January 2010 Revised March 2017 Contents Paragraph Page 1 Aim 4 2 Introduction 4 3 Assessment of renal function
More informationIxazomib with Lenalidomide and Dexamethasone (IRd)
Indication Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma for patients who have already had 2 or 3 lines of
More informationCiclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml
Shared Care Protocol Ciclosporin for the treatment of rheumatoid arthritis Name of drug, form and strength Background Ciclosporin 25mg, 50mg, 100mg capsules Ciclosporin oral solution 100mg/ml Ciclosporin
More informationBEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL
Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*
More informationPatient Group Direction for SALBUTAMOL INHALER (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More information